Eli Lilly has entered a research collaboration and exclusive license agreement with Precision BioSciences to use genome editing to develop therapies for genetic disorders.
It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership with MaxCyte, and Precision BioSciences filing for a $100 million IPO for its ‘off-the-shelf’ cancer cell therapies.